Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biotronik SE & Co. KG | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this registry study is to collect information about routine clinical practices with device implantation to treat bradycardia and cardiac systolic dysfunction (heart rhythm disorders) across global centers of excellence in cardiac pacing. In particular, this study will examine the use of conduction system pacing (CSP) in clinical practice. Information collected in the registry will help researchers better characterize strengths and limitations of current technology and treatments.
During this past decade, there has been a dramatic surge in interest in new physiologic pacing strategies which engage and take advantage of the intrinsic cardiac conduction system. These approaches include His bundle pacing (HBP) as well as approaches which seek to pace the proximal left conduction system (LCS), including left bundle branch area pacing (LBBAP) or pacing in the region of the left posterior fascicle. Left ventricular septal pacing (LVS) has also been proposed as another means to avoid dyssynchrony with early data suggestive of comparable electrical synchronization as biventricular pacing. These approaches utilize approved pacing systems and leads which are delivered to new targets in the His-Purkinje system or LV endocardial fibers. Despite the growing interest in HBP, LCS, and LVS, the majority of data are from disparate cohort studies and there has been a lack of uniformity in assembling data or analyzing and interpreting outcomes.
The goal of the Conduction System Pacing International Registry (CONSPIRE) is to systematically and prospectively collect data across multiple centers of excellence on the early implementation of permanent conduction system pacing devices in order to characterize strengths and limitations of current technology. The study will evaluate patient selection, intraprocedural characteristics, and clinical outcomes among patients receiving conduction system pacing (CSP) as part of their routine clinical care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Individuals receiving conduction system pacing |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Data collection | Other | Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use. |
| Measure | Description | Time Frame |
|---|---|---|
| Implant characteristics | Data will be collected on CSP lead position based on reported anatomical position (e.g., His bundle location, left bundle branch area or left bundle branch pacing location, or left ventricular septal pacing location) | Month 0, during procedure |
| QRS duration measured by electrocardiography at baseline | Data will be collected on QRS duration (milliseconds) prior to implant | Baseline, within 1 month prior to procedure |
| QRS morphology captured by surface electrocardiography at baseline | Data will be collected on QRS morphology (e.g., narrow QRS, left bundle branch block, right bundle branch block, left anterior or posterior hemiblock, nonspecific intraventricular conduction delay, or predominantly paced QRS) prior to implant | Baseline, within 1 month prior to procedure |
| QRS duration measured by electrocardiography after implant | Data will be collected on QRS duration (milliseconds) after implant procedure | Month 0, pre discharge |
| QRS morphology captured by surface electrocardiography after implant | Data will be collected on QRS morphology [e.g., narrow QRS, left bundaloid QRS in V1, or right bundaloid QRS in V1] after implant procedure | Month 0, pre discharge |
| Procedure-related complications | Data will be collected to characterize procedure-related complications | Through 12 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals receiving conduction system pacing
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gaurav A Upadhyay, MD | University of Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85719 | United States | ||
| University of Chicago |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001919 | Bradycardia |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D003625 | Data Collection |
| ID | Term |
|---|---|
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
| Changes in left ventricular ejection fraction |
Data will be collected to characterize changes in left ventricular ejection fraction |
| Through 12 months |
| Changes in chamber dimension | Data will be collected to characterize changes in chamber dimension | Through 12 months |
| Heart failure hospitalizations | Data will be collected to characterize heart failure hospitalizations within the first 12 months after device implant | Through 12 months |
| Any-cause mortalities | Data will be collected to characterize any-cause mortalities within the first 12 months after device implant | Through 12 months |
| Sustained ventricular arrhythmia occurrences | Data will be collected to characterize sustained ventricular arrhythmia occurrences | Through 12 months |
| System-related complications | Data will be collected to characterize system-related complications | Through 12 months |
| Lead-related complications | Data will be collected to characterize lead-related complications | Through 12 months |
| Chicago |
| Illinois |
| 60637 |
| United States |
| Icahn School of Medicine at Mount Sinai & Mount Sinai Hospital | New York | New York | 10029 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Geisinger Wyoming Valley Medical Center | Wilkes-Barre | Pennsylvania | 18711 | United States |
| Maastricht University Medical Center | Maastricht | Netherlands |
| Health Research Institute Hospital La Fe | Valencia | Spain |
| Lund University | Lund | Sweden |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |